Neurotone AI Expands Lace Adoption to 1,000 Clinics

Neurotone AI has surpassed 1,000 clinic partners globally, 18 months after launching Lace AI Pro in July 2024. Deployment includes the broader Lace product family, including Tinnitus Pro, and training is offered in 10 languages. Clinics report clinical and commercial benefits, and trade coverage in February 2026 highlighted aural rehabilitation as vital to device outcomes.

Lace combines rule-based and machine-learning personalization to adapt exercise difficulty and content in real time. Key capabilities include:

• •AI-driven personalization that adjusts tasks based on user performance and contextual signals
• •Adaptive exercise pacing and difficulty to maintain target challenge levels
• •Clinician dashboards for remote monitoring, adherence tracking, and outcome reporting

These features let patients complete structured aural-rehabilitation regimens at home while clinicians monitor progress without adding significant in-clinic time.

Aural rehabilitation has long been part of professional standards, but consistent delivery was constrained by clinic time and staffing. Lace AI Pro operationalizes rehabilitation as a scalable digital-therapeutic offering, aligning clinical best practices with productized software. For the broader AI-in-healthcare trend, this is an example of domain-specific ML creating measurable workflow leverage: it moves clinical effort out of the clinic, supports longitudinal outcomes tracking, and converts a therapy modality into a billable, trackable service. Early adopter feedback calls out both patient benefit and revenue upside, which accelerates uptake among practices.

Adoption metrics and published clinical outcomes will determine whether Lace transitions from a useful adjunct to an evidence-backed standard of care. Payor reimbursement, integration with EHR workflows, and peer-reviewed outcome studies are the next levers that will decide large-scale clinical adoption and long-term impact.